| Literature DB >> 33312124 |
Li Li1, Dan-Ni Yao2, Yue Lu1, Jing-Wen Deng2, Jian-An Wei1, Yu-Hong Yan2, Hao Deng2, Ling Han1, Chuan-Jian Lu2.
Abstract
Psoriasis is a chronic, refractory, systemic inflammatory skin disease. Traditional Chinese medicine (TCM) shows unique advantage in the treatment of psoriasis based on syndrome differentiation. An untargeted high-throughput metabonomics method based on liquid chromatography coupled to mass spectrometry was applied to study the serum metabolic characteristics in different TCM syndrome types in patients with psoriasis vulgaris (PV), and to discover potential serum biomarkers for its pathogenesis on the endogenous metabolite differentiation basis. The serum metabolic profiles of 45 healthy controls and 124 patients with PV (50 in the blood-stasis group, 30 in the blood-heat group, and 44 in the blood-dryness group) were acquired. The raw spectrometric data were processed using multivariate statistical analysis, and 14 biomarkers related to TCM syndrome differentiation and psoriasis types were screened and identified. The blood-stasis syndrome group showed abnormal lipid metabolism, which was characterized by a low level of phosphatidylcholine (PC) and a high level of lysophosphatidylcholine (LPC). We propose that platelet-activating factor can be applied as a potential biomarker in clinical diagnosis and differentiation of PV with blood-stasis syndrome. The difference in the serum metabolites among PV types with different TCM syndromes and healthy control group illustrated the objective material basis in TCM syndrome differentiation and classification of psoriasis.Entities:
Keywords: biomarker; blood-stasis syndrome; metabonomics; psoriasis; traditional Chinese medicine syndrome
Year: 2020 PMID: 33312124 PMCID: PMC7708332 DOI: 10.3389/fphar.2020.558731
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Clinical characteristics of psoriasis vulgari patients with different TCM syndromes and healthy controls.
| TCM Syndrome (Cases) | Male age (Average ± SD) (Cases) | Female age (Average ± SD) (Cases) |
|---|---|---|
| Blood-stasis(50) | 42.0 ± 9.8 (30) | 44.2 ± 10.9(20) |
| Blood-dryness(44) | 42.9 ± 11.6 (26) | 44.3 ± 13.6(18) |
| Blood-heat(30) | 43.3 ± 9.4 (24) | 51.2 ± 18.8 (6) |
| Healthy control(45) | 40.1 ± 9.1 (24) | 41.2 ± 8.1 (21) |
Figure 1The total ion chromatograms (TIC) operating under positive ion mode. There were differences among the metabolic profilings of psoriasis vulgaris patients groups with blood-stasis, blood-heat, and blood-dryness and healthy control group.
Figure 2Multivariate data analysis and permutation test (A) OPLS-DA scores map, (B) Permutation test of OPLS-DA, (C) Loading map of PLS-DA.
Potential biomarkers identification.
| No. | m/z | Compound | Chemical Formula | Adducts | HMDB ID | Trend* |
|---|---|---|---|---|---|---|
| 1 | 524.370 | Platelet-activating factor | C26H54NO7P | M+H | HMDB0062195 | ↑ |
| 2 | 496.338 | LysoPC(16:0) | C24H50NO7P | M+H | HMDB0010382 | ↑ |
| 3 | 520.337 | LysoPC(18:2) | C26H50NO7P | M+H | HMDB0010386 | ↑ |
| 4 | 522.354 | LysoPC(18:1) | C26H52NO7P | M+H | HMDB0002815 | ↑ |
| 5 | 550.385 | LysoPC(20:1) | C28H56NO7P | M+H | HMDB10391 | ↑ |
| 6 | 544.340 | LysoPC(20:4) | C28H50NO7P | M+H | HMDB10395 | ↑ |
| 7 | 835.528 | PI(18:0/16:2) | C43H79O13P | M+H | HMDB09807 | ↑ |
| 8 | 613.393 | Cholestane-3,7,12,25-tetrol-3-glucuronide | C33H56O10 | M+H | HMDB10355 | ↑ |
| 9 | 782.570 | PC(18:3/18:1) | C44H80NO8P | M+H | HMDB0008170 | ↓ |
| 10 | 806.571 | PC(22:5/16:1) | C46H80NO8P | M+H | HMDB0008660 | ↓ |
| 11 | 810.601 | PC(20:4/18:0) | C46H84NO8P | M+H | HMDB0008464 | ↓ |
| 13 | 806.561 | Lactosylceramide (d18:1/12:0) | C42H79NO13 | M+H | HMDB04866 | ↓ |
| 14 | 313.155 | Phenylalanylphenylalanine | C18H20N2O3 | M+H | HMDB13302 | ↓ |
*The trend was psoriasis groups compared to healthy control group.
Fourteen significant difference metabolites were screened out to be the potential biomarkers according to the value of variable importance for projection (VIP) value in PLS-DA model.
Figure 3Typical metabolites with significant alterations. The peaks area of potential biomarkers in serum of the four groups were shown.
Figure 4The ROC curve plots and boxplot of PAF (A) Blood-stasis vs Healthy controls; (B) Blood-stasis vs Blood dryness; (C) Blood-stasis vs Blood-heat.